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Objectives: Praziquantel is the only drug available for the treatment of schistosomiasis and the state of the
exhausted drug discovery pipeline is alarming. We restarted investigations on the abandoned antischistosomal
Ro 13-3978, an aryl hydantoin discovered in the early 1980s by Hoffmann La-Roche.
Methods: Newly transformed schistosomula and adult Schistosoma mansoni were studied in the presence of Ro
13-3978 in vitro. The metabolic stability of Ro 13-3978 was determined in vitro using human and mouse liver S9
fractions. Dose–response relationship, stage specificity, hepatic shift and scanning electron microscopy studies
were carried out in S. mansoni-infected mice. In addition, efficacy experiments were conducted in rodents
infected with Echinostoma caproni and Fasciola hepatica as well as in S. mansoni-infected immunocompromised
nude (Foxn1nu) mice.
Results: Ro 13-3978 showed minor in vitro activity and no damage to the tegument was found. No cytotoxicity
was detected for Ro 13-3978. Ro 13-3978 was metabolically stable. ED50 values of 138.9 and 14.6 mg/kg were
calculated for the treatment of juvenile and adult S. mansoni infections, respectively, with a single oral dose of Ro
13-3978. SEM studies revealed severe damage to the worms 48 h post-treatment of infected mice. A single oral
dose of Ro 13-3978 (100 mg/kg) administered to S. mansoni-infected (Foxn1nu) mice reduced the worm burden
by 88%. Ro 13-3978 was not active against E. caproni and F. hepatica in vivo.
Conclusions: Ro 13-3978 has excellent antischistosomal properties in vivo. Structure–activity relationship studies
with the aryl hydantoins have been launched in order to elucidate active pharmacophores, further investigate the
mechanism of action and to identify a derivative with minimal antiandrogenic effects.
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Introduction
Schistosomiasis is a waterborne parasitic infection caused by
six different trematode species, with Schistosoma mansoni,
Schistosoma haematobium and Schistosoma japonicum being
responsible for the largest public health burden.1,2 The disease
gives rise to a persistent chronic disorder in endemic areas, result-
ing in common disabling complications such as anaemia, growth
stunting, cognitive impairment and decreased aerobic capacity.2,3
Using the most recent disability-adjusted life year (DALY) metrics,4
an estimated 3.3 million DALYs have been attributed to schisto-
somiasis. To reduce the chronic health burden, millions of school-
age children are treated each year in the framework of ‘preventive
chemotherapy’ programmes with praziquantel.5 Praziquantel is a
safe and effective drug against the chronic stage of the disease;
however, it is the only commercially available drug for the treat-
ment and control of schistosomiasis.5,6 Since the introduction of
praziquantel several decades ago, drug discovery and develop-
ment for this neglected tropical disease have been minimal and
no backup drug is therefore available should praziquantel-
resistant parasites evolve.6
In the early 1980s, Hoffmann La-Roche discovered the anti-
schistosomal aryl hydantoin Ro 13-3978. The compound, a
close structural analogue of the androgen receptor antagonist
nilutamide, is a distant chemical cousin of the nitrothiazole, imi-
dazolidinone niridazole7 (Figure 1), an obsolete schistosomicide,
but is otherwise chemically unrelated to known antischistosomal
drugs. We recently demonstrated that a single 400 mg/kg dose of
nilutamide achieved a high worm burden reduction (WBR) in
S. mansoni-infected mice.8 Furthermore, we showed that there
is no correlation between antischistosomal activity and androgen
receptor interaction for nilutamide, Ro 13-3978 and closely
related aryl hydantoins.9 Drug discovery efforts by Hoffmann
La-Roche revealed that Ro 13-3978 was equal to or more effective
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than praziquantel in different in vivo schistosome animal models;
thus the compound was recommended for clinical testing.10
However, despite its remarkable and broad-spectrum activity,
Ro 13-3978 was not further investigated.
The aim of the present study was to draw attention to the
largely forgotten Ro 13-3978 by a thorough re-examination of
its antischistosomal properties. In vitro studies with Ro 13-3978
were conducted against newly transformed schistosomula (NTS)
and adult S. mansoni. Cytotoxicity studies were carried out using
rat skeletal myoblast L6 cells. The dose–response relationship and
stage specificity were evaluated in S. mansoni-infected mice. To
begin to understand the pharmacokinetic/pharmacodynamic
profile and mechanism of action of Ro 13-3978, metabolic stabil-
ity, hepatic shift and scanning electron microscopy (SEM) studies
and efficacy experiments in immunocompromised mice and mice
treated with 1-aminobenzotriazole, a non-specific inhibitor of
cytochrome P450, were conducted.
Materials and methods
Animals and parasites
In vivo experiments were carried out at the Swiss Tropical and Public Health
Institute (Basel, Switzerland), in accordance with Swiss national and can-
tonal regulations on animal welfare (permission no. 2070). Female mice
(NMRI strain, n¼86; weight 20–22 g) and female rats (n¼6; weight
80 g) were purchased from Charles River, Germany. Ten NMRI nude
mice (weight 18–20 g) were purchased from Harlan, the Netherlands.
Rodents were kept under environmentally controlled conditions (tempera-
ture 258C; humidity 70%; 12 h light and 12 h dark cycle) and acclima-
tized for 1 week before infection. The animals had free access to water and
rodent diet.
Cercariae of S. mansoni and Echinostoma caproni were obtained from
infected intermediate host snails (Biomphalaria glabrata) as described pre-
viously.11 Fasciola hepatica metacercariae were purchased from Baldwin
Aquatics, USA.
Compounds
Ro 13-3978 was synthesized as previously described.10,12 For in vitro anti-
schistosomal studies, compounds were dissolved in DMSO (Fluka, Buchs,
Switzerland) to obtain 10 mg/mL stock solutions. For in vivo studies, com-
pounds were suspended in 7% (v/v) Tween 80 (Fluka, Buchs, Switzerland)
and 3% (v/v) ethanol before oral administration to rodents (10 mL/kg).
In vitro studies
NTS
S. mansoni cercariae were harvested from infected snails and mechanic-
ally transformed to NTS as described earlier.13 An NTS suspension at a
concentration of 100 NTS per 50 mL was prepared using Medium 199
(Invitrogen, Carlsbad, CA, USA) supplemented with 5% inactivated FCS
(iFCS; Connectorate AG, Dietikon, Switzerland) and 100 U/mL penicillin and
100 mg/mL streptomycin (Invitrogen). NTS suspensions were incubated
(378C, 5% CO2) for at least 24 h before experiments to ensure that conver-
sion into schistosomula had been completed. NTS were incubated with
100 mg/mL Ro 13-3978 for 72 h at 378C, 5% CO2. The experiment was con-
ducted in triplicate and repeated once. The highest concentration of DMSO
served as a control. NTS were evaluated by microscopic readout (Carl Zeiss,
Germany, magnification×80) using a viability scale scoring death, changes
in motility, viability and morphological alterations.13
Adult S. mansoni
Adult schistosomes were removed by picking from the hepatic portal
system and mesenteric veins of mice that had been infected with 100
S. mansoni cercariae 49 days earlier. The worms were washed and kept
in RPMI 1640 culture medium (Invitrogen) supplemented with antibiotics
and 5% iFCS at 378C in an atmosphere of 5% CO2 until use. In one experi-
ment, the medium was supplemented with a freshly prepared haemin
solution (8%) or 2% (v/v) human red blood cells (RBCs: blood group AB,
Rh positive) to test whether haemoglobin degradation is involved in the
mechanism of action.14 Worms were incubated in the presence of 25–
100 mg/mL Ro 13-3978 for up to 96 h. Phenotypes were monitored
daily, scoring motility, viability and morphological alterations under an
inverted microscope (Carl Zeiss, Germany, magnification×80), using the
viability scale mentioned above. In addition, membrane damage was
checked by a Trypan Blue exclusion assay: Ro 13-3978-treated, live control
and dead control worms (killed using a cell lysis buffer) were rinsed three
times with non-enriched RPMI medium, then exposed to a solution of 50
mL of Trypan Blue (Invitrogen) in 500 mL of non-enriched RPMI for 10 min.
Worms were then returned to the culture medium and checked for Trypan
Blue staining. All experiments with adult S. mansoni were conducted in
duplicate and repeated once.
Cytotoxicity studies on rat skeletal myoblast L6 cells
Cytotoxicity studies were conducted as described elsewhere.15 Briefly, rat
skeletal myoblast L6 cells were seeded in 96-well plates (2×103 cells/well)
(BD Falcon, USA) using RPMI 1640 medium supplemented with 10% iFCS
and 1.7 mM L-glutamine (Sigma-Aldrich, Buchs, Switzerland). Following
adhesion of the cells for 24 h at 378C and 5% CO2, the IC50 of Ro
13-3978 was determined using concentrations of 0.12, 0.37, 1.11, 3.33,
10, 30 and 90 mM. Podophyllotoxin (Sigma-Aldrich) served as positive con-
trol. At 70 h post-incubation, 10 mL of resazurin dye (Sigma-Aldrich) was
added and the plates incubated for another 2 h. The plates were then
read using a SpectraMax M2 (Molecular Devices) plate reader with an exci-
tation wavelength of 530 nm and an emission wavelength of 590 nm. The
cytotoxicity experiment was conducted in duplicate and repeated
three times.
Metabolic stability experiments
The in vitro metabolic stability of Ro 13-3978 was determined using human
and mouse liver S9 fractions (XenoTech, LLC, Lenexa, KS, USA) following
standard protocols.16,17 Briefly, Ro 13-3978 (2 mM in 0.1% methanol)
was premixed with NADPH (1 mM), saccharolactone (5 mM), uridine
5′-diphospho-glucuronic acid (1 mM) and 3′-phosphoadenosin-5′-
phosphosulphate (0.1 mM) in potassium phosphate buffer (100 mM, pH
7.4) at 378C. Reactions were initiated by adding S9 fractions at 1 mg/mL pro-
tein concentration in final incubation volumes of 100 mL and were then
quenched by adding 100 mL of ice-cold methanol at 0, 5, 10, 15, 30, 45,
60, 90 and 120 min, followed by centrifugation at 17000 g for 10 min.
Ten microlitres of the supernatants were then analysed by LC-MS/MS
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Figure 1. Structures of Ro 13-3978, nilutamide and niridazole.
Ro 13-3978, a broad-spectrum antischistosomal
1789
JAC
using an Acquity UPLC-BEH Shield RP18 column (2.1×100 mm, 1.7 mm;
Waters, Milford, MA, USA) with a 2:3 0.1% acetic acid:methanol isocratic
mobile phase at a flow rate of 0.25 mL/min. MS/MS analyses were per-
formed in negative electrospray ionization mode; specific detection of Ro
13-3978 was performed by monitoring the transition 288.9177.9 m/z.
For the detection of potential Ro 13-3978 metabolites, multiple reac-
tion monitoring– information-dependent acquisition-enhanced product
ion, neutral loss, precursor ion and enhanced MS scans were used.
7-Hydroxycoumarin and testosterone were used as control substrates for
phase I and phase II metabolism.
In vivo studies
E. caproni
Mice were infected orally with 20–25 metacercarial cysts of E. caproni.
Fourteen days post-infection, four mice were treated with a single oral
100 mg/kg Ro 13-3978 dose. Four untreated mice served as controls.
One week post-treatment, mice were killed and dissected, and all
worms present in the intestines counted.
F. hepatica
Six rats were infected with 20–25 F. hepatica metacercariae. Twelve weeks
post-infection, three rats were treated with a single oral 100 mg/kg Ro
13-3978 dose while three rats remained untreated. One week post-
treatment, livers and bile ducts were examined for flukes and worm bur-
dens were calculated.
S. mansoni
To study the dose–response relationship of Ro 13-3978 in adult S. mansoni
infections, groups of three to five NMRI mice were treated orally in a single
experiment with single doses of Ro 13-3978 (12.5, 25, 50 and 100 mg/kg)
at 49 days post-infection. To test whether metabolism contributes to the
activity of Ro 13-3978, one group of mice (n¼5) infected with adult
S. mansoni was orally treated with 50 mg/kg 1-aminobenzotriazole
(Sigma-Aldrich) followed by 100 mg/kg Ro 13-3978, 2 h later. To assess
whether a potential interaction of Ro 13-3978 with the immune response
plays a role in its antischistosomal efficacy, immunocompromised NMRI
nude mice (n¼5) were treated with a single 100 mg/kg oral dose of Ro
13-3978, 49 days post-infection.
Mice (four to five mice per group) harbouring juvenile infections (estab-
lished 3 weeks post-infection) were treated orally in a single experiment
with doses of Ro 13-3978 (25, 50, 100 and 200 mg/kg).
For the stage-specificity experiment, groups of four mice were treated
with a single oral 100 mg/kg Ro 13-3978 dose, 2 and 1 day prior to infec-
tion with S. mansoni cercariae, on infection day and on days 7, 14, 22, 28,
35, 42 and 49 post-infection.
Untreated mice served as controls in all experiments. At day 21 post-
treatment (days 21–49 for the stage-specificity experiment), animals
were killed by the CO2 method and dissected. Worms were removed by
picking, then sexed and counted as previously described.18
Finally, the hepatic shift was investigated as follows. Four mice infected
with adult schistosomes were orally treated with 100 mg/kg Ro 13-3978
and after 4, 8, 28 and 48 h, one mouse was euthanized and dissected. All
worms in the mesenteric veins, hepatic portal veins and pressed liver were
counted.
SEM studies
SEM studies were conducted for both in vitro and in vivo Ro 13-3978-
treated worms. In vitro worms were incubated as described above with
25–100 mg/mL Ro 13-3978 for 72 h. For the in vivo studies, two mice
were orally treated with 100 mg/kg Ro 13-3978 and dissected at 24 and
48 h post-treatment. Worms were extracted from the mesenteric veins
and liver as described above, rinsed twice in PBS, and fixed in 1 mL 2.5%
glutaraldehyde for 3–24 h at room temperature. Subsequently, samples
were dehydrated by incubating the worms for 30 min in ascending ethanol
concentrations of 30, 50, 70, 90 and 100%. The worms were critically
point-dried (Bomar SPC-900), mounted on aluminium stubs and sputter-
coated with gold of 20 nm particle size (Baltec Med 020). Samples were
visualized using a high-resolution SEM accelerating voltage of 5 kV
(Philips XL30 ESEM). Control worms (untreated; Figure 4a–d) were pre-
pared and visualized in the same manner.
Statistics
Parasite viability values of treated and untreated NTS and adult schisto-
somes obtained from microscopic evaluation were averaged (means+SD)
Table 1. Dose–response relationship of Ro 13-3978 in mice harbouring juvenile and adult S. mansoni
Stage of
infection
Dosage
(mg/kg)
No. of mice
investigated
No. of
mice
cured
Mean number of worms (SD)
Total
WBR
(%) P value
Female
WBR (%) P valueliver
mesenteric
veins total males females
control 1 8 — 1.0 (1.5) 24.8 (8.0) 25.9 (7.4) 11.1 (4.2) 14.8 (3.2) — — — —
control 2 9 — 1.3 (1.9) 24.0 (5.5) 25.3 (5.3) 13.0 (2.6) 12.3 (3.4) — — — —
control 3 9 0.9 (1.2) 16.6 (5.2) 17.4 (5.1) 8.6 (3.3) 8.9 (3.4) — — — —
control 4 10 1.9 (1.8) 26.0 (13.8) 27.9 (14.4) 15.4 (8.1) 12.5 (7.0) — — — —
Juvenile 501 4 0 0 (0) 27.3 (11.8) 27.3 (11.8) 10.3 (4.3) 17.0 (7.8) 0 0.005 0 0.01
1003a 4 0 2.3 (2.1) 4.0 (3.6) 6.3 (4.3) 2.5 (0.6) 3.8 (3.9) 63.8 57.3
2002a 5 0 1.0 (1.0) 2.0 (1.6) 3.0 (1.9) 1.2 (0.8) 1.8 (1.3) 88.1 85.4
Adult 12.51 4 0 0.5 (1.0) 15.8 (11.6) 16.3 (12.4) 6.5 (4.1) 9.8 (8.8) 37.1 ,0.001 33.8 ,0.001
251 4 1 0.3 (0.5) 4.3 (5.4) 4.5 (5.3) 2.3 (2.6) 2.3 (2.6) 82.6 84.5
503 4 1 0.3 (0.5) 3.5 (2.6) 3.8 (2.8) 0 (0) 3.8 (2.8) 78.2 57.3
1004a 4 2 0.3 (0.5) 1.3 (1.5) 1.5 (1.9) 0 (0) 1.5 (1.9) 94.6 88.0
aData reproduced from Wang et al.,9 superscripts refer to the respective control group (1–4).
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using Microsoft Excel software. For in vivo studies, WBRs were determined by
calculating the percentage reduction in mean worm burdens of the treat-
ment groups relative to the untreated mice and the Kruskal–Wallis test
was used to test for significance (P≤0.5; StatsDirect statistical software, ver-
sion 2.7.2.; StatsDirect Ltd, UK). The 50% effective dose values (ED50) were
calculated using CompuSyn software (Version 3.0.1, 2007; ComboSyn
Inc., USA).
Results
In vitro studies
Ro 13-3978 was tested against adult S. mansoni and NTS in vitro.
Ro 13-3978 at 100 mg/mL moderately reduced the motility of
both the schistosomula and adults at 24, 48 and 72 h post-
incubation. Incubation with 25 or 50 mg/mL Ro 13-3978 produced
the same result, although the slowed motility became pro-
nounced only at ≥72 h. Occasional spasms were also observed
in the adult worms. Both microscopic evaluation and the Trypan
Blue exclusion test indicated no damage to the tegument. A simi-
lar behaviour of worms was observed in the presence of haemin.
The addition of 2% RBC to the medium resulted in the death of
worms at 100 mg/mL, but at lower concentrations (25 and
50 mg/mL) worms were still alive 72 h post-incubation with only
slightly decreased motility. No cytotoxicity was detected for Ro
13-3978 (IC50 .90 mM).
Metabolic stability of Ro 13-3978
Ro 13-3978 was stable (.95%) in both human and mouse liver S9
fractions for up to 120 min, and no metabolites were detected
using LC-MS/MS analysis. In contrast, under the same conditions,
more than 65% of the positive controls 7-hydroxycoumarin (glu-
curonidation and sulphation) and testosterone (CYP hydroxyl-
ation) had been consumed within 30 min incubation (data
not shown).
Dose–response relationship against juvenile and adult
S. mansoni in vivo
In contrast to the marginal in vitro activity of Ro 13-3978, single
oral doses of this aryl hydantoin showed high in vivo antischisto-
somal efficacies. Total and female WBRs following treatment
of juvenile S. mansoni infections (22 days post-infection) with
50–200 mg/kg Ro 13-3978 and of adult S. mansoni infections
(49 days post-infection) with 12.5–100 mg/kg Ro 13-3978 are
summarized in Table 1. Adult S. mansoni infections were more
susceptible to the compound than juvenile infections. Total and
female WBRs of 88.2% and 85.4%, respectively, were observed
with 200 mg/kg Ro 13-3978 against juvenile infections. In mice
infected with adult S. mansoni, a single 100 mg/kg oral dose of
Ro 13-3978 reduced total and female worm burden by 94.6%
and 88.0%. From these data, ED50 values of 138.9 and 14.6 mg/kg
were calculated for treatment with Ro 13-3978 of mice harbouring
22 and 49 day-old S. mansoni infections, respectively.
Stage specificity of single oral 100 mg/kg Ro 13-3978
in mice harbouring S. mansoni
Given the lower activity of Ro 13-3978 against 22 day-old com-
pared with 49 day-old S. mansoni, the entire stage specificity of
Ro 13-3978 was tested in mice. Mice were treated with Ro
13-3978 1 and 2 days prior to infection, on infection day and on
days 7, 14, 22, 28, 35, 42 and 49 post-infection (Figure 2). Seven
and 14 day-old S. mansoni were not affected by the compound.
Moderate WBRs (32.4%–66.8%) were observed in mice treated
with 100 mg/kg Ro 13-3978 before infection. High activities
(64.3%–94.6%) were documented in mice treated with Ro
13-3978 in weekly intervals from day 22 onwards.
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Figure 2. Stage specificity of single oral 100 mg/kg Ro 13-3978 in mice
harbouring S. mansoni. Groups of four mice were treated 2 and 1 day
prior to infection with S. mansoni cercariae, on infection day and on
days 7, 14, 22, 28, 35, 42 and 49 post-infection. Worm burden reduction
was evaluated 21–49 days post-treatment.
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Figure 3. Hepatic shift observed in mice harbouring S. mansoni following
100 mg/kg Ro 13-3978. One mouse was dissected at 4, 8, 28 or 48 h
post-treatment and worms were counted in the liver and mesenteric
veins. Light grey bars, number of worms alive in the mesenteric veins;
black bars, number of worms alive in the liver; and dark grey bars,
number of dead worms found in the liver.
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 4. SEM observations of in vitro untreated and Ro 13-3978-treated (100 mg/mL for 72 h) worms. (a and b) Male control worms show a healthy
tegument: tubercles (T) and spine (S) are intact and the tegument in-between is ridged and taut. Female control worms (c and d) are marked by a ridged
(R) texture. Treated male worms (e and f) show a slight puffing and wrinkling (wr) of the between-tubercle tegument and some tubercles have a less
rounded shape and fewer spikes. Female treated worms were mostly unaffected. However, two female worms (g and h) exhibit some areas of sloughing
(sl) and a loss of ridged texture (no R). High magnification scans (×8000; b, d and f) reveal no differences between the control and treated worms, except
that male treated worms appear to have slightly more pores (P; part f).
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Figure 5. SEM observations of untreated worms and worms extracted from mice treated with 100 mg/kg Ro 13-3978, 24 and 48 h post-treatment.
(a–d) Tegument of control worms with intact tubercles (T) and spines (S). OS, VS and GC denote oral sucker, ventral sucker and gynecophoral canal,
respectively. (e–h) At 24 h there is mild damage to the male and female worms. For male worms, the tegument between the tubercles exhibits
extensive wrinkling (wr) and some tubercles exhibit rupturing (r). The female worms lose features—the ridges (R) found in the control worms start to
disappear. (i– l) At 48 h, extensive damage to the tegument is observed: along with wrinkling and rupturing (l), massive blebbing (bl), sloughing (sl) and
general disintegration (di) are apparent along the entire length of the worm.
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Hepatic shift
Figure 3 depicts the distribution of worms in the liver and the mes-
enteric veins. Four hours post-treatment, all worms were present
in the mesenteric veins. Eight hours post-treatment, the first
worms had shifted to the liver, but the majority of worms still
resided in the mesenteric veins and all worms were still alive.
Most of the worms had shifted to the liver 28 h post-treatment
and all of these showed clearly reduced viability. On the next
day (48 h post-treatment), all worms had died and the majority
of worms had been expelled.
SEM studies
As reported above, in vitro-treated worms showed moderately
slowed activity at 72 h without an apparent change to the tegu-
ment. SEM examinations of the male worms revealed no obvious
changes in tegument, except that it appeared less taut (Figure 4e
and f). Most female worms appeared unaffected; however, two
female worms from the 100 and 25 mg/mL treatment arms
were marked by a few patches of mild to moderate sloughing
and a few patches where a loss of ridged texture had occurred
(Figure 4g and h). In S. mansoni-infected mice treated with a
100 mg/kg oral dose of Ro 13-3978, a progressive effect was
observed (Figure 5). At 24 h post-treatment (Figure 5e–h), the
worms were slightly more contorted. The tegument was still
mostly intact; however, the areas between the tubercles were
very wrinkled and small ruptures could be seen on the external
tegument at the edges of the gynecophoral canal as well as the
edges of the oral sucker. Moreover, the female tegument had
started to lose its ridged texture (parallel ridges disappeared). At
48 h post-treatment, severe damage to the worms could be
observed throughout all regions. The tegument showed blebbing,
sloughing and rupturing all along the body, as well as the head
and suckers (Figure 5i– l), and the edges of the gynecophoral
canal were deeply furrowed.
Activity of Ro 13-3978 in immunocompromised mice
and mice pretreated with 1-aminobenzotriazole
To further elucidate whether active metabolites or immunological
mechanisms might help to account for the striking difference
between the in vitro and in vivo activity of Ro 13-3978, further in
vivo studies were conducted (Table 2). We found that very similar
percentage WBR values were observed when single 100 mg/kg
oral doses of Ro 13-3978 were administered to S.mansoni-infected
mice with (100% WBR) and without (95% WBR) pretreatment with
1-aminobenzotriazole as a pan-CYP450 inhibitor, an unsurprising
result given that this aryl hydantoin appears to be metabolically
inert (see above). The same dose of Ro 13-3978 administered to
S. mansoni-infected immunocompromised nude (Foxn1nu) mice
reduced the worm burden by 88%.
Activity of Ro 13-3978 against E. caproni and F. hepatica
We tested whether Ro 13-3978 exhibits blood fluke-specific in vivo
activity or whether the range of activity would also include the
liver fluke F. hepatica and the intestinal fluke E. caproni. No effect
(i) (j)
(k) (l)
Figure 5. Continued.
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on the worm burden was observed when rodents infected with
these two trematode species were treated with 100 mg/kg oral
doses of Ro 13-3978 (Table 3).
Discussion
At least 230 million people worldwide are infected with
Schistosoma spp.,2 yet we only have the lone drug praziquantel
for treatment and control of this neglected tropical disease. A
recent systematic review, which assessed the state of the
research and development pipeline of drugs and vaccines for
neglected diseases, highlighted a clear deficiency in this field.19
No drug is currently undergoing clinical testing for schistosomia-
sis;19 hence a backup drug will not be available in the next decade.
We restarted investigations on Ro 13-3978, an aryl hydantoin
with excellent antischistosomal properties, discovered in the early
1980s by Hoffmann La-Roche.10 Our experiments confirmed that
Ro 13-3978 has high activity against S. mansoni in the mouse
model, with mature S. mansoni being more susceptible to the
drug than juvenile flukes. We found that Ro 13-3978 had a single
oral ED50 of 15 mg/kg in S. mansoni-infected mice (adult worms),
a value close to the previously reported ED50 of 38 mg/kg.
10 In this
same schistosome mouse model, praziquantel is considerably
less effective against adult S. mansoni, with reported ED50 values
ranging from 172 to 202 mg/kg,10,20 and it has no significant
activity against juvenile stages of the parasite. In contrast, in
mice infected with juvenile S. mansoni, Ro 13-3978 had a single
oral ED50 of 140 mg/kg. Interestingly, 7 and 14 day-old worms
were not affected by Ro 13-3978, which might be explained by
the location of the developing worm in the host (worms migrate
via the heart and lungs to the liver, where they establish after
2.5 weeks).21
Considerable unpublished preclinical data on Ro 13-3978 have
been generated by Hoffmann La-Roche, ranging from parasito-
logical to toxicological studies. Most importantly, Ro 13-3978 is
active against all three major schistosome species—S. mansoni,
S. haematobium and S. japonicum.10 When Ro 13-3978 was admi-
nistered to three different monkey species (Cebus monkeys,
baboons and Erythrocebus monkeys) infected with S. mansoni,
high activity was observed.10 Our studies further document
that, in contrast to praziquantel, the activity of Ro 13-3978 is
schistosome-specific with no activity observed on the intestinal
fluke E. caproni and the liver fluke F. hepatica. A range of toxicology
studies were conducted at Hoffmann La-Roche, which confirmed
that the drug is safe when administered at a single dose (unpub-
lished data). For this class of aryl hydantoins, antiandrogenic effects
were observed in multiple-dose studies using male castrated rats,12
which is likely to be of less concern with single-dose treatment regi-
mens. A recent study9 demonstrated that, in contrast to nilutamide,
Ro 13-3978 had no measurable interaction with the androgen
receptor at concentrations up to 27 mM (7.8 mg/mL), although it
did block dihydrotestosterone-induced cell proliferation in an
androgen-dependent cell line.
The mechanism of action of Ro 13-3978 is not known; particu-
larly striking is the difference between its in vitro and in vivo effi-
cacy. In in vitro assays, worms were slightly affected by Ro
13-3978; only moderate impairment to motility was seen and
only at very high concentrations. Interestingly, supplementation
of the medium with 2% RBC resulted in the death of worms,Ta
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although only at a high concentration of 100 mg/mL. Further,
SEM studies showed no membrane damage for most worms—
results that, based on in vitro data alone, would have dismissed
Ro 13-3978 from any further consideration. Yet in vivo studies
have repeatedly confirmed the high activity of this compound.
From the data that we have generated to date, the lack of signifi-
cant in vitro activity of Ro 13-3978 is not explained by active meta-
bolites or by effects on host immunology. In fact, experiments
using human and mouse S9 fractions and 1-aminobenzotriazole-
treated S. mansoni-infected mice indicate that Ro 13-3978 is not
metabolized. Our data with the largely T cell-deficient Foxn1nu
mice suggests that cytotoxic T cell activity is not required for Ro
13-3978 to effectively clear adult S. mansoni from the host. On
the other hand, the antischistosomal drugs oxamniquine and prazi-
quantel were found to kill fewer adult S. mansoni worms in T cell-
deprived mice than in immunologically intact controls.22 However,
T cell-independent worm antigens may be released or unveiled fol-
lowing Ro 13-3978 treatment, allowing for a humoral response to
either be generated or effectively coat the adult worm in vivo.
Further studies are in progress to identify the most likely mechan-
isms that might account for the high in vivo efficacy of Ro 13-3978.
The hepatic shift, which characterizes the forced migration of
schistosomes to the liver, indicates that the onset of action of Ro
13-3978 starts rather slowly—at around 1 day post-treatment.
For comparison, in parallel experiments with praziquantel, by
30 min post-treatment, the majority of worms shift to the
liver.23 Mefloquine, another recently identified antischistosomal
agent, showed a hepatic shift 72 h post-treatment.24
SEM studies corroborate the slow onset of action of Ro
13-3978. At 24 h post-treatment, all of the worms were still
found in the mesenteric veins and the corresponding images
show that the worms are still mostly intact, although some dam-
age (occasional ruptures in the tegument) can be seen. At 48 h
post-treatment, the damage is clearly visible throughout the
worm: the tegument is completely disintegrated, characterized
by blebbing, rupturing and sloughing. At this time point, the vast
majority of the worms were shifted to the liver and the females
expelled. Damage to the tegument is likely not caused by the hep-
atic shift, as previous non-effective treatments, e.g. the inactive
enantiomer of praziquantel (S-praziquantel),23 have also caused
a hepatic shift, followed by a return to the mesenteric veins,
with the worms completely intact and viable.
In conclusion, we have confirmed that Ro 13-3978 has excel-
lent antischistosomal properties against juvenile and adult
S. mansoni infections in vivo. The aryl hydantoins should be con-
sidered candidates for the antischistosomal drug discovery
and development pipeline. Structure–activity relationship studies
have been launched to identify a derivative with minimal antian-
drogenic effects to elucidate active pharmacophores and to
further investigate the mechanism of action of this com-
pound class.
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